Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.

Abstract

We conducted a phase II study of combination chemotherapy with nedaplatin (NP) with irinotecan (CPT) to determine the effects against unresectable non-small cell lung cancer (NSCLC) and to determine the qualitative and quantitative toxicities of this combination chemotherapy in 70 years or older patients. Thirty-eight patients received 100 mg/m2 NP on day 1 and 60 mg/m2 CPT on days 1 and 8 every four weeks. Twenty-five patients achieved PR, nine SD and three PD, and the overall response rate was 65.8%. Nineteen patients (50%) experienced grade 4 neutropenia. Neutropenic fever occurred in 11 patients (29%) and one of them died. Of other grade 3 non-hematologic toxicities, two patients experienced diarrhea; one interstitial pneumonitis; one liver injury; and one rash. The median survival time was 418 days and the one-year survival rate was 55.3%. In conclusion, NP combined with CPT is an active treatment for elderly patients with NSCLC.

• Authors: Fumihiro Oshita, Kouzo Yamada, Haruhiro Saito, Kazumasa Noda, Nobuyuki Hamanaka, Mizuki Ikehara
• Journal: Journal of experimental therapeutics & oncology (J Exp Ther Oncol) Vol. 4 Issue 4 Pg. 343-8 (Dec 2004) ISSN: 1359-4117 [Print] United States
• PMID: 15844664 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Antineoplastic Agents, Phytogenic
• Organoplatinum Compounds
• Irinotecan
• nedaplatin
• Camptothecin

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Agents (pharmacology)
• Antineoplastic Agents, Phytogenic (pharmacology)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Camptothecin (administration & dosage, analogs & derivatives)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Disease Progression
• Female
• Humans
• Irinotecan
• Lung Neoplasms (drug therapy)
• Male
• Organoplatinum Compounds (administration & dosage)
• Time Factors
• Treatment Outcome